Table 1.
Patient characteristics for all 131I-BC8 studied and treated patients receiving BU/CY alone
| Characteristic | All 131I-BC8 studied patients | All 131I-BC8 treated patients |
|---|---|---|
| Number of patients | 52 | 46 |
| Median age, y (range) | 41 (16-55) | 42.5 (16-55) |
| Median WBCs × 109/L at diagnosis (range) | 9.8 (0.6-180) | 12.9 (0.6-180) |
| FAB classification*, no. (%) | ||
| M0 | 2 (3.8) | 1 (2.2) |
| M1 | 9 (17) | 9 (20) |
| M2 | 11 (21) | 8 (17) |
| M3 | 0 (0) | 0 (0) |
| M4 | 14 (27) | 13 (28) |
| M5 | 7 (13) | 6 (13) |
| M6 | 1 (1.9) | 1 (2.2) |
| M7 | 1 (1.9) | 1 (2.2) |
| ND | 7 (13) | 7 (15) |
| Cytogenetic risk group†, no. (%) | ||
| Favorable | 1 (1.9) | 1 (2.2) |
| Intermediate | 30 (58) | 26 (57) |
| Unfavorable (high) | 16 (31) | 15 (33) |
| ND | 5 (9.6) | 4 (8.7) |
| More than 1 cycle of chemotherapy to achieve CR1, no. (%) | 24 (46) | 20 (44) |
| 3 or fewer mo from CR1 to HCT, no. (%) | NA | 10 (22) |
| No. of consolidation courses, no. of patients (%) | ||
| 0 | 15 (29) | 15 (33) |
| Fewer than 2 cycles | 23 (44) | 21 (46) |
| 2 or more cycles | 9 (17) | 9 (20) |
| Unknown | 5 (9.6) | 1 (2.2) |
| Secondary AML/MDS, no. (%) | 6 (12) | 5 (11) |
| Source of stem cells, no. (%) | ||
| Bone marrow | NA | 40 (87) |
| Peripheral blood | NA | 6 (13) |
WBC indicates white blood cell count; ND, not determined; MDS, myelodysplastic syndrome; NA, not applicable.
*
French-American-British classification of blast morphology
†
Southwest Oncology Group criteria